Daratumumab: Difference between revisions
From IDWiki
mNo edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
== Background == |
|||
* Anti-CD38 antibody used in the treatment of [[multiple myeloma]] |
|||
* IgG1K human monoclonal antibody targetting CD38 |
|||
| ⚫ | |||
* Indications include [[multiple myeloma]] |
|||
== Adverse Effects == |
|||
* Adverse effects include [[hypertension]] (10%), edema, fatigue, cytopenias including anemia, liver enzyme abnormalities, infusion reactions (35% with first infusion), cytokine release syndrome, anaphylaxis, electrolyte abnormalities, headache (10%), insomnia, cough, dyspnea, rhinitis |
|||
| ⚫ | |||
== Further Reading == |
|||
* [https://www.cancercareontario.ca/en/system/files_force/daratumumab.pdf?download=1 Cancer Care Ontario drug monograph] |
|||
[[Category:Medications]] |
[[Category:Medications]] |
||
Latest revision as of 15:03, 9 February 2023
Background
- IgG1K human monoclonal antibody targetting CD38
- Indications include multiple myeloma
Adverse Effects
- Adverse effects include hypertension (10%), edema, fatigue, cytopenias including anemia, liver enzyme abnormalities, infusion reactions (35% with first infusion), cytokine release syndrome, anaphylaxis, electrolyte abnormalities, headache (10%), insomnia, cough, dyspnea, rhinitis
- Risk of infections, including CMV, HSV, and possible hepatitis B
